(2R,6S,12Z,14aR,16aS)-6-{[(cyclopentyloxy)carbonyl]amino}-2-[(7-methoxy-2-{2-[(1-methylethyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,6S,12Z,14aR,16aS)-6-{[(cyclopentyloxy)carbonyl]amino}-2-[(7-methoxy-2-{2-[(1-methylethyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a
• 英文别名: (1S,4R,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
• 化学式: C₄₀H₅₀N₆O₈S
• 分子量: 774.9
• InChiKey: PJZPDFUUXKKDNB-CJXSQDHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  55
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  210
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
  申请人：White E. Ronald

  公开号：US20070021351A1

  公开（公告）日：2007-01-25

  Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating activity of HCV protease, in which liver to plasma concentration ratio of the compound ranges from about 2:1 to about 10:1.

  提供了包括至少一种从本文中定义的I到XXVI式化合物组中选择的化合物的组合物和治疗组合，以及治疗、预防或改善丙型肝炎的一个或多个症状的方法，治疗与HCV病毒相关的疾病，调节HCV蛋白酶活性，其中化合物的肝脏到血浆浓度比范围约为2:1至约为10:1。
• Chimeric antigen receptor (CAR) modulation
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US11059864B2

  公开（公告）日：2021-07-13

  The technology described herein is directed to CAR polypeptides and systems comprising repressible proteases. In combination with a specific protease inhibitor, the activity of said CAR polypeptides and systems and cells comprising them can be modulated. Also described herein are methods of using said CAR polypeptides and systems, for example to treat various diseases and disorders.

  本文所述技术针对的是包含可抑制蛋白酶的 CAR 多肽和系统。结合特定的蛋白酶抑制剂，可以调节所述 CAR 多肽和系统以及包含它们的细胞的活性。本文还描述了使用所述 CAR 多肽和系统的方法，例如用于治疗各种疾病和失调。
• Regulated synthetic gene expression systems
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US11530246B2

  公开（公告）日：2022-12-20

  The technology described herein is directed to regulated synthetic gene expression systems. In one aspect described herein are synthetic transcription factors (synTFs) comprising a DNA binding domain, a transcriptional effector domain, and a regulator protein. In other aspects described herein are gene expression systems comprising said synTFs and methods of treating diseases and disorders using said synTFs.

  本文所述技术针对的是受调控的合成基因表达系统。一方面，本文所述的合成转录因子（synTFs）包括 DNA 结合结构域、转录效应结构域和调节蛋白。在其他方面，本文所述的基因表达系统包括所述的合成转录因子和使用所述合成转录因子治疗疾病和失调的方法。
• Crystalline phases of a potent HCV inhibitor
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040229777A1

  公开（公告）日：2004-11-18

  This invention relates to novel crystalline phases of the following Compound (1), methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: 1

  本发明涉及下列化合物（1）的新型晶相、其制备方法、其药物组合物及其在治疗丙型肝炎病毒（HCV）感染中的用途：1
• Class of surfactant-like materials
  申请人：Li Jinjiang

  公开号：US20060068007A1

  公开（公告）日：2006-03-30

  This invention generally refers to a novel class of surfactant-like material that promotes the solubility of poorly soluble compounds.

  本发明泛指一类新型的类表面活性剂材料，它能促进溶解性差的化合物的溶解。